![]() |
Acta Pharmacologica Sinica 2008 March; 29 (3): 305-319; doi: 10.1111/j.1745-7254.2008.00760.x |
| Original Article | [ Full text ] |
| Agonist-induced hump current production in heterologously-expressed human α4β2-nicotinic acetylcholine receptors1 |
Qiang LIU2, Ke-wei YU2, Yong-chang CHANG3, Ronald J LUKAS3, Jie WU2,4 Divisions of 2Neurology and 3Neurobiology, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona 85013-4496, USA |
Methods: Whole-cell and outside-out patch recordings were performed using human α4β2-nAChR heterologously expressed in stably-transfected, native nAChR-null subclonal human epithelial 1 (SH-EP1) cells. RT-PCR was used to test the mRNA expression of transfected nAChR. Homology modeling and acetylcholine (ACh) docking were applied to show the possible ACh-binding site in the channel pore.
Results: The rapid exposure of 10 mmol/L ACh induced an inward current with a decline from peak to steady-state. However, after the removal of ACh, an additional inward current, called "hump" current, reoccurred. The ability of agonists to produce these hump currents cannot be easily explained based on drug size, charge, acute potency, or actions as full or partial agonists. Hump currents were associated with a rebound increase in whole-cell conductance, and they had voltage dependence-like peak currents induced by agonist action. Hump currents blocked by the α4β2-nAChR antagonist dihydro-β-erythroidine were reduced when α4β2-nAChR were desensitized, and were more pronounced in the absence of external Ca2+. Outside-out single-channel recordings demonstrated that compared to 1 µmol/L nicotine, 100 µmol/L nicotine reduced channel current amplitude, shortened the channel mean open time, and prolonged the channel mean closed time, supporting an agonist-induced open-channel block before hump current production. A docking model also simulated the agonist-binding site in the channel pore.
|
Keywords: acetylcholine; dihydro-β-erythroidine; dimethyl-phenyl-piperazinium; epibatidine; nicotinic acetylcholine receptor |
| 1 This work was supported by endowment and capitalization funds from the Men's and Women's Boards of the Barrow Neurological Foundation and Epi-Hab Phoenix, and by grants from the Arizona Disease Control Research Commission (No 5011 and 10011), the Arizona Alzheimer's Disease Core Center (Pilot grant), and the National Institutes of Health (No NS040417 and DA015389). |
|
[ Full text ] |
Copyright©APS 2009 Add: 294 Tai-Yuan Road, Shanghai 200031, China Phn: 86-21-5492-2821 Fax: 86-21-5492-2823 E-mail: aps@mail.shcnc.ac.cn |